10-Q: Organogenesis Q3 2025: Revenue Up, ReNu Trial Misses Endpoint

Organogenesis Holdings Inc. reports a 31% increase in Q3 2025 net product revenue, driven by new products, but its second Phase 3 ReNu trial for knee OA did not achieve statistical significance for its primary endpoint.

Summary

• Net product revenue for Q3 2025 increased by 31% to $150.487 million, compared to $115.177 million in Q3 2024.
• Net product revenue for the nine months ended September 30, 2025, decreased by 5% to $337.959 million, from $355.387 million in the same period of 2024.
• Advanced Wound Care net product revenue for Q3 2025 was $141.451 million, up 31% from $107.953 million in Q3 2024.
• Advanced Wound Care net product revenue for the nine months ended September 30, 2025, decreased by 6% to $314.074 million, primarily due to increased ambiguity and disruption in customer behavior following delayed LCD implementation.
• Surgical & Sports Medicine net product revenue for Q3 2025 increased by 25% to $9.036 million, and by 17% to $23.885 million for the nine months ended September 30, 2025.
• Net income for Q3 2025 was $21.567 million, an increase from $12.331 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $(6.668) million, compared to a net loss of $(6.812) million in the same period of 2024.
• Adjusted EBITDA for Q3 2025 increased to $30.119 million from $13.410 million in Q3 2024.
• Adjusted EBITDA for the nine months ended September 30, 2025, decreased to $13.955 million from $31.610 million in the same period of 2024.
• The second Phase 3 Randomized Controlled Trial (RCT) of ReNu for knee osteoarthritis did not achieve statistical significance for its primary endpoint (p=0.0393 vs. target threshold p=0.023).
• Dermagraft manufacturing transition to the new Smithfield, RI facility is expected to begin in 2027, with sales resuming by the end of 2027.
• New Local Coverage Determinations (LCDs) for skin substitute grafts/CTPs for DFUs and VLUs have been delayed until January 1, 2026, and would classify over 200 products as non-covered, including PuraPly, PuraPly AM, PuraPly XT, Novachor, TransCyte, Dual, and Matrix.
• CMS finalized a Physician Fee Schedule (PFS) rule and proposed an Outpatient Prospective Payment System (OPPS) rule for 2026, which will pay for certain skin substitute products at approximately $127.28 per square centimeter, aligning categorization with FDA regulatory status.
• Cash and cash equivalents were $63.745 million as of September 30, 2025, down from $135.571 million at December 31, 2024.
• Working capital was $205.1 million as of September 30, 2025.
• The Revolving Credit Facility was reduced from $125 million to $75 million on October 31, 2025, and new financial covenants were added, including a minimum Consolidated Interest Coverage Ratio of 3x and a Consolidated Capital Expenditures covenant of less than $50 million under certain conditions.

Sentiment

Score: 4

Explanation: While Q3 revenue and net income showed growth, the nine-month performance was negatively impacted by regulatory uncertainty. The failure of the ReNu Phase 3 trial to meet its primary endpoint is a significant setback for a pipeline product, introducing substantial uncertainty regarding its future commercialization. The reduction in the revolving credit facility and substantial cash burn from operations also contribute to a cautious outlook.

Positives

• Net product revenue increased by 31% in Q3 2025 compared to Q3 2024, driven by newly licensed products and increased sales to existing and new customers.
• Surgical & Sports Medicine net product revenue increased by 25% in Q3 2025 and 17% in the nine months ended September 30, 2025, due to increased customer buying patterns.
• Net income for Q3 2025 was $21.567 million, a significant improvement from $12.331 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 increased to $30.119 million from $13.410 million in Q3 2024.
• ReNu demonstrated a numerical improvement in baseline pain reduction (-6.9 in second Phase 3 study vs. -6.0 in first Phase 3 study) and continued a favorable safety profile.
• CMS payment structure changes are believed to curb abuse and ensure consistent payment across sites of care.
• The company expects cash on hand, working capital, and Revolving Facility availability to fund operations for at least 12 months.

Negatives

• Net product revenue decreased by 5% for the nine months ended September 30, 2025, primarily due to increased ambiguity and disruption in customer behavior following delayed LCD implementation.
• Advanced Wound Care net product revenue decreased by 6% for the nine months ended September 30, 2025, due to LCD implementation delays.
• The second Phase 3 RCT of ReNu did not achieve statistical significance for its primary endpoint (p=0.0393, missing target threshold p=0.023).
• More than 200 products, including key products like PuraPly, PuraPly AM, PuraPly XT, Novachor, TransCyte, Dual, and Matrix, would be classified as non-covered under the new LCDs if implemented.
• CMS payment policy changes could materially impact utilization of products, business, revenue, and profitability.
• Cash and cash equivalents decreased significantly from $135.571 million at December 31, 2024, to $63.745 million at September 30, 2025.
• Net cash used in operating activities was $(49.729) million for the nine months ended September 30, 2025, compared to $3.271 million provided in the same period of 2024.
• The Revolving Credit Facility was reduced from $125 million to $75 million.
• Accumulated deficit increased to $(46.778) million at September 30, 2025, from $(40.110) million at December 31, 2024.
• A write-down to fair value for an asset held for sale of $922 thousand was recognized in Q3 2025 and $9.235 million for the nine months ended September 30, 2025.

Risks

• Uncertainty regarding further delays, revisions, or rescission of new Local Coverage Determinations (LCDs). If implemented, the new LCDs could materially impact utilization of affected products, business, and revenue.
• CMS payment policy changes for Medicare payments under the Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) for skin substitute products in calendar year 2026 could materially impact utilization of products, business, revenue, and profitability.
• The second Phase 3 Randomized Controlled Trial (RCT) of ReNu did not achieve statistical significance for its primary endpoint, which could have a material adverse effect on the commercial application of ReNu.
• Uncertainty if the FDA will accept the current data package for ReNu BLA submission or require additional data, with no guarantee of BLA approval.
• Even if ReNu BLA is approved, the clinical data may not be sufficient for payers to cover and/or adequately reimburse customers for product use.
• The FDA may limit ReNu indications for use or place other conditions on approval, which could restrict its commercial application.
• Significant delays in the build-out of the Smithfield Facility or FDA approval for Dermagraft manufacturing could adversely affect future consolidated net product revenue and results of operations.
• Reliance on estimates and assumptions in financial statements, which may differ significantly from actual results.
• Exposure to credit risk on cash deposits exceeding federally insured limits.
• Potential for increased selling, general, and administrative expenses due to investments in market development and sales force expansion.
• Regulatory actions, including healthcare reimbursement scenarios, may require costly expenditures or result in pricing pressures, decreasing gross profit.
• The company may not be able to obtain additional funds on acceptable terms or at all, if necessary to meet long-term liquidity needs.
• Legal proceedings, though currently deemed immaterial, are inherently unpredictable and subject to significant uncertainties.

Future Outlook

The company expects to resume sales of Dermagraft by the end of 2027, following a manufacturing transition to its new Smithfield, Rhode Island facility, which is anticipated to begin in 2027 and yield significant capacity and long-term cost savings. A meeting with the FDA is scheduled for December 12, 2025, to discuss the Biologics License Application (BLA) submission for ReNu, potentially utilizing combined efficacy analysis from both Phase 3 studies. CMS intends to propose differentiated payment rates for skin substitute products based on FDA regulatory categories in future years. The company anticipates recognizing grant income related to the Smithfield Facility through 2027 and expects selling, general, and administrative expenses to increase due to investments in market development and sales force expansion. Management believes current cash, working capital, and Revolving Facility availability will fund operations for at least 12 months, with potential for additional equity or debt financings for long-term liquidity. The company plans to adopt ASU 2023-09 (Income Taxes) in Q4 2025 and is evaluating the impact of other recently issued accounting standards.

Management Comments

• We believe CMS finalized PFS payment structure and proposed OPPS payment structure will curb abuse under the current system, and the resulting rapid escalation in Medicare spending, and ensure a much-needed consistent payment approach across sites of care.
• We expect to resume sales of Dermagraft by the end of 2027.
• We expect that our cash on hand and other components of working capital as of September 30, 2025, availability under the Revolving Facility, plus net cash flows from product sales will be sufficient to fund our operating expenses, capital expenditure requirements and debt service payments for at least 12 months beyond the filing date of this Form 10-Q.
• We generally expect our selling, general and administrative expenses to continue to increase due to increased investments in market development and the geographic expansion of our sales forces as we drive for continued revenue growth.

Industry Context

Organogenesis operates in the regenerative medicine and tissue innovations market, focusing on advanced wound care and surgical/sports medicine, a sector driven by aging demographics and increasing prevalence of comorbidities such as diabetes and cardiovascular disease. The industry is currently navigating significant regulatory changes, including new Local Coverage Determinations (LCDs) and CMS payment rules, which are expected to reshape product coverage and reimbursement. The company emphasizes its FDA approvals and clinical data as a competitive differentiator in a market characterized by high development costs and extensive regulatory pathways.

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings.
• From time to time, the company may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business, including intellectual property, employment, and general claims.
• Management believes the ultimate resolution of such claims would not have a material effect on the financial position, operating results, or cash flows of the company.

Related Party Transactions

• Lease obligations exist with related parties (65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC) for office and laboratory space in Canton, Massachusetts, where the owners of these entities are also directors, former directors, and/or stockholders of the company.
• In November 2024, the company repurchased 7,921,731 shares of Class A common stock from certain existing stockholders, including certain directors and their affiliates, using proceeds from the Series A Convertible Preferred Stock.
• Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P. became related parties after purchasing Series A Convertible Preferred Stock in November 2024.

Stakeholder Impact

• Shareholders face potential negative impact from the ReNu trial miss and regulatory uncertainty affecting revenue, as well as potential dilution from stock-based compensation and convertible preferred stock.
• Employees are affected by restructuring charges and headcount-related expenses, but also benefit from stock-based compensation plans.
• Customers are impacted by delayed LCD implementation and potential non-coverage of certain products, leading to 'ambiguity and disruption in customer behavior,' and CMS payment changes could also affect utilization.
• Creditors (Lenders) are subject to amended credit agreement terms, including a reduced Revolving Facility and new financial covenants, but the company expects to fund debt service payments for at least 12 months.

Next Steps

• Meeting with the FDA on December 12, 2025, to discuss the BLA submission for ReNu, including potentially using combined efficacy analysis from both Phase 3 studies.
• Transition Dermagraft manufacturing to the Smithfield, Rhode Island facility, expected to begin in 2027.
• Resume Dermagraft sales by the end of 2027.
• Evaluate the broader effects of the One Big Beautiful Bill Act (OBBBA) as further guidance is issued.
• Plan to adopt ASU 2023-09 (Income Taxes) in Q4 2025 and expand income tax disclosures in the 2025 Annual Report.
• Continue evaluating the impact of ASU 2024-03 (Income Statement Expenses), ASU 2025-05 (Credit Losses for Accounts Receivable), and ASU 2025-06 (Internal-Use Software).

Key Dates

Recommendation

While the company demonstrated some resilience with Q3 revenue growth and improved net income, the overall nine-month performance is weaker. The failure of the ReNu Phase 3 trial to meet its primary endpoint is a significant setback for a key pipeline asset, introducing substantial uncertainty regarding its future commercialization. Furthermore, the ongoing delays and potential negative impact of new Medicare coverage determinations on a large portion of the product portfolio create significant headwinds. The reduction in the revolving credit facility and substantial cash burn from operations also contribute to a cautious outlook. Until there is more clarity on ReNu's path forward and the full impact of the CMS policy changes, a 'Hold' recommendation is appropriate.

Keywords

Regenerative medicine, Wound care, Surgical medicine, Sports medicine, Biotechnology, Medical devices, FDA approval, ReNu, Dermagraft, Apligraf, CMS, Medicare, Clinical trials, Financial results, Quarterly report, SEC filing